In this highly regulated industry, life sciences companies must overcome a variety of challenges. Early development stage companies face a long process of getting their devices and/or drugs approved. They may invest millions before research and development is complete. The level of financial reporting needs to match the level of sophistication of the funding source. Weaver can provide support for managing costs, gaining access to capital, financial reporting, mergers and acquisitions and taking companies public.
Both “essential” and “non-essential” businesses are experiencing the impact of COVID-19 on their operations and bottom line. Business owners are looking to their commercial property insurance policy as a means of minimizing or recovering revenue shortfalls by filing COVID business interruption insurance claims, construction claims and other property damage claims related to the pandemic. Read More
Importers suffering “significant financial hardship” related to COVID-19 have an extra 90 days to pay tariffs. The U.S. Treasury Department and U.S. Customs and Border Protection (CBP) issued a joint temporary final rule detailing a 90-day deferment on the payment of duties, taxes and fees for certain goods imported, or withdrawn from a warehouse, in March or April 2020. Read More
On this episode of Weaver's Beyond the Numbers podcast, host Shelby Skrhak sat down with Jody Allred, Partner-in-Charge for Large Market Manufacturing and Distribution and Technology Services, and Kurtis Dixon, Partner in Tax Services to discuss critical issues facing manufacturing industry leaders who are seeking guidance on handling the unprecedented COVID-19 pandemic. Read More